32 / 36
recaída
CheckMate 238
a
Patients may have received more than one type of post-protocol therapy and more than one agent within each type. All percentages are based on total number of
patients in each group.
b
May include patients treated with NIVO+IPI combination.
c
May include patients treated with BRAF+MEK combination.
d
Includes tumor resection
for diagnostic purposes and biopsies
Treatment, n (%)
a
NIVO
(n = 453)
IPI
(n = 453)
Any
141 (31.1)
186 (41.1)
Systemic therapy
100 (22.1)
151 (33.3)
Chemotherapy
28 (6.2)
30 (6.6)
Immunotherapy
60 (13.2)
119 (26.3)
Nivolumab
b
20 (4.4)
52 (11.5)
Pembrolizumab
Anti-PD-1 agent
13 (2.9)
1 (0.2)
72 (15.9)
2 (0.4)
Ipilimumab
b
44 (9.7)
19 (4.2)
Other CTLA-4 inhibitor
1 (0.2)
1 (0.2)
BRAF inhibitor
c
47 (10.4)
45 (9.9)
MEK inhibitor
c
38 (8.4)
46 (10.2)
Surgery
d
73 (16.1)
68 (15.0)
Radiotherapy
26 (5.7)
27 (6.0)
Weber J et al. Presented at ASCO 2018; abstract 9502.